ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

IMGN Company Profile and Key Details

NASDAQ : IMGN

ImmunoGen, Inc.

$31.24

0.005+0.02%

At Close 4:00 PM

Not Actively Trading

65.48

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

IMGN Stock Price Chart

Stock Price Today

ImmunoGen, Inc. (IMGN) stock surged +0.02%, trading at $31.24 on NASDAQ, up from the previous close of $31.23. The stock opened at $31.24, fluctuating between $31.22 and $31.25 in the recent session.

Stock Snapshot

31.23

Prev. Close

31.24

Open

8.73B

Market Cap

279.35M

Number of Shares

31.22

Day Low

31.25

Day High

-111.55357142857143

P/E Ratio

88.72%

Free Float in %

-0.28

EPS (TTM)

1.95

Book Value

-0.69

Cash Flow per Share

19.31M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 13, 2024	31.23	31.23	31.23	31.23	0
Feb 12, 2024	31.23	31.23	31.23	31.23	0
Feb 09, 2024	31.24	31.25	31.22	31.23	48.61M
Feb 08, 2024	31.23	31.24	31.22	31.23	49.31M
Feb 07, 2024	29.50	29.69	29.41	29.55	10.52M
Feb 06, 2024	29.31	29.55	29.25	29.51	8.6M
Feb 05, 2024	29.26	29.39	29.24	29.30	4.86M
Feb 02, 2024	29.36	29.47	29.21	29.26	6.35M
Feb 01, 2024	29.35	29.48	29.26	29.36	3.12M
Jan 31, 2024	29.53	29.60	29.15	29.32	6.27M
Jan 30, 2024	29.48	29.54	29.37	29.39	3.92M
Jan 29, 2024	29.57	29.62	29.35	29.42	3.99M
Jan 26, 2024	29.53	29.57	29.49	29.57	2.69M
Jan 25, 2024	29.56	29.58	29.49	29.50	4.43M
Jan 24, 2024	29.50	29.54	29.42	29.50	2.98M
Jan 23, 2024	29.59	29.59	29.44	29.44	6.15M
Jan 22, 2024	29.53	29.62	29.52	29.54	5.12M
Jan 19, 2024	29.58	29.61	29.51	29.52	3.43M
Jan 18, 2024	29.63	29.63	29.51	29.53	4.54M
Jan 17, 2024	29.62	29.70	29.57	29.59	2.43M

Contact Details

Waltham, MA 02451-1477

United States

Website: https://www.immunogen.comContact: 781 895 0600

About Company

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Frequently Asked Questions

What is the current ImmunoGen, Inc. (IMGN) stock price?

ImmunoGen, Inc. (NASDAQ: IMGN) stock price is $31.24 in the last trading session. During the trading session, IMGN stock reached the peak price of $31.25 while $31.22 was the lowest point it dropped to. The percentage change in IMGN stock occurred in the recent session was 0.02% while the dollar amount for the price change in IMGN stock was $0.01.

IMGN's industry and sector of operation?

The NASDAQ listed IMGN is part of Biotechnology industry that operates in the broader Healthcare sector. ImmunoGen, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IMGN?

Ms. Susan Altschuller Ph.D.
Senior Vice President & Chief Financial Officer
Mr. Daniel S. Char J.D.
Senior Vice President, Chief Legal Officer & Sec.
Mr. Joseph J. Kenny
Vice President, Acting Gen. Counsel, Intellectual Property & Sec.
Ms. Renee Lentini
Interim Chief Financial Officer, Vice President of Fin. & Chief Accounting Officer
Dr. Mary Margaret Huizinga FACP, M.D., M.P.H.
Senior Vice President & Head of Medical Affairs
Dr. Susan Altschuller Ph.D.
Senior Vice President & Chief Financial Officer (Leave of Absence)
Dr. Massimo Radaelli M.B.A., Ph.D.
Senior Vice President & GM of International
Mr. Mark Joseph Enyedy
Pres, Chief Executive Officer & Director
Dr. Anna Berkenblit M.D., MM.Sc
Senior Vice President & Chief Medical Officer
Ms. Stacy A. Coen
Senior Vice President & Chief Bus. Officer
Dr. Michael J. Vasconcelles M.D., Ph.D.
Executive Vice President of Research, Devel. & Medical Affairs
Ms. Courtney O'Konek
Senior Director of Corporation Communications & Investor Relations
Ms. Audrey Bergan
Senior Vice President & Chief HR Officer
Dr. Theresa G. Wingrove
Senior Vice President of Regulatory Affairs & Quality
Anabel Chan
Head of Investor Relations

How IMGN did perform over past 52-week?

IMGN's closing price is 765.24% higher than its 52-week low of $3.61 where as its distance from 52-week high of $31.25 is -0.05%.

How many employees does IMGN have?

Number of IMGN employees currently stands at 277.

Link for IMGN official website?

Official Website of IMGN is: https://www.immunogen.com

How do I contact IMGN?

IMGN could be contacted at phone 781 895 0600 and can also be accessed through its website. IMGN operates from 830 Winter Street, Waltham, MA 02451-1477, United States.

How many shares of IMGN are traded daily?

IMGN stock volume for the day was 19.31M shares. The average number of IMGN shares traded daily for last 3 months was 8.29M.

What is the market cap of IMGN currently?

The market value of IMGN currently stands at $8.73B with its latest stock price at $31.24 and 279.35M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	277
Beta	1.17
Sales or Revenue	$108.78M
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology